News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
美FDA將審議放寬多肽產品限制 Hims & Hers(HIMS.US)股價升5%
美國食品及藥物管理局(FDA)將於7月舉行為期兩日的諮詢委員會會議，討論是否允許持牌配製藥房重新製造部分於2023年被禁的多肽產品。Hims & Hers(HIMS.US)股價上升5%，延續前一交易日14%升勢。是次審議涵蓋7種多肽，相關產品被宣稱可用於傷口癒合、減重及改善失眠等用途，但人體安全數據仍有限。(me/t)~阿思達克財經新聞網址: www...
Reset
Send
The window will close in 5 seconds
美FDA將審議放寬多肽產品限制 Hims & Hers(HIMS.US)股價升5%
Close
Recommend
1
Positive
1
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

美國食品及藥物管理局(FDA)將於7月舉行為期兩日的諮詢委員會會議，討論是否允許持牌配製藥房重新製造部分於2023年被禁的多肽產品。Hims & Hers(HIMS.US)      股價上升5%，延續前一交易日14%升勢。

是次審議涵蓋7種多肽，相關產品被宣稱可用於傷口癒合、減重及改善失眠等用途，但人體安全數據仍有限。

(me/t)(Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.